A recent study suggests that CDK6-deficient cancer cells that rely on the function of CDK4 in cell cycle progression are sensitive to these inhibitors; in contrast, upregulation of CDK6 in breast cancer cells promotes CDK4/6 inhibitor resistance [50–52]. Here, CDK4 is linked to breast cancer.